Lake Street Maintains Hold on CVRx, Lowers Price Target to $1.5
William Blair Downgrades CVRx to Market Perform
CVRx (CVRX) Q3 2026 Earnings Call Transcript
CVRx, Inc. (CVRX) Q3 2026 Earnings Call Transcript
Canaccord Genuity Downgrades CVRx to Hold, Lowers Price Target to $2
CVRx Inc (CVRX) Q3 2026 Earnings Call Highlights: Revenue Misses Guidance as Reimbursement ...
Here's What Key Metrics Tell Us About CVRx (CVRX) Q3 Earnings
CVRx: Q3 Earnings Snapshot
CVRx Reports Third Quarter 2026 Financial and Operating Results
CVRx Lowers FY2026 Sales Guidance from $58.000M-$60.000M to $56.000M-$57.000M vs $58.950M Est
CVRx to Participate in Upcoming Investor Conferences
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
CVRx Reports Q2 2026 Results: Full Earnings Call Transcript
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
CVRx To Present Barostim Data And Clinical Research At HFSA Annual Scientific Meeting 2026
CVRx Appoints John Landry as Chief Financial Officer
CVRx Appoints John Landry CFO, Effective Oct. 12, Succeeding Jared Oasheim
CVRx Responds to Letter from Pointillist Family Office
Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.